MACROGENICS INC
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- MGNXMacroGenics0Calm
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Signing up patientsPhase 280 patientsMain results: Jul 2027 - MGNXMacroGenics0Calm
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
FinishedPhase 2154 patientsMain results: Feb 19, 2026 - MGNXMacroGenics0Calm
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
FinishedPhase 2/382 patientsMain results: Jan 15, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
1 sale (0 not pre-planned) · 0 purchases
- Peters Jeffrey StuartSenior VP, GC, and Secretary · Aug 19, 2026Sold 31,105 sharesabout $129 thousand · pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- An executive or board member joined or left; Shared information with investorsNews report (8-K)Nov 3, 2026
- Other newsNews report (8-K)Oct 23, 2026
- Correction to a news reportCorrection to a news report (8-K/A)Sep 3, 2026
- Quarterly reportQuarterly report (10-Q)Aug 14, 2026
- Shared quarterly resultsNews report (8-K)Aug 13, 2026